Inspira Technologies Oxy B.H.N. (IINN) 6-K 29 Sep 22 Interim Condensed Financial Statements Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	Inspira Technologies Oxy B.H.N. Ltd.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001837493
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity File Number	001-40303

Unaudited Interim Condensed Sta

Unaudited Interim Condensed Statements of Financial Position - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 14,154	$ 23,749
Deposits	5,020
Other accounts receivable	195	639
Restricted cash	67	120
Total current assets	19,436	24,508
Non-Current Assets:
Right of use assets, net	1,101	1,160
Property, plant and equipment, net	208	202
Total non-current assets	1,309	1,362
Total Assets	20,745	25,870
Current Liabilities:
Trade accounts payables	50	93
Other accounts payable	1,114	725
Lease liabilities	309	281
Financial Liabilities at fair value	439	3,215
Total current liabilities	1,912	4,314
Non-Current Liabilities:
Lease liabilities	787	900
Loan from the Israeli Innovation Authority	293	302
Total non- current liabilities	1,080	1,202
Shareholders’ Equity:
Share capital and additional paid-in capital	52,042	48,935
Foreign exchange reserve	(2,025)	210
Accumulated deficit	(32,264)	(28,791)
Total deficit	17,753	20,354
Total Liabilities and Shareholders’ Equity	$ 20,745	$ 25,870

Unaudited Interim Condensed S_2

Unaudited Interim Condensed Statements of Comprehensive Loss - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Profit or loss [abstract]
Research and development expenses	$ 4,294	$ 1,104
Sales and marketing expenses	777	244
General and administrative expenses	2,936	1,210
Operating loss	8,007	2,558
Finance expense (income)	(4,534)	5,732
Loss before tax	3,473	8,290
Taxes on income
Total net loss	3,473	8,290
Other comprehensive loss, net of tax:
Exchange losses arising on translation to presentation currency	(2,235)	33
Total comprehensive loss	$ 5,708	$ 8,323
Weighted average number of ordinary shares (in Shares)	10,475,392	2,667,207
Basic and diluted loss per share (in Dollars per share)	$ (0.54)	$ (3.11)

Unaudited Interim Condensed S_3

Unaudited Interim Condensed Statements of Comprehensive Loss (Parentheticals) - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Profit or loss [abstract]
Basic and diluted loss per share (in Dollars per share)	$ (0.54)	$ (3.11)

Unaudited Interim Condensed S_4

Unaudited Interim Condensed Statements of Changes in Shareholders' Equity Deficiency - USD ($) $ in Thousands	Share capital	Additional paid-in capital	Adjustments arising from translating financial operation	Accumulated deficit	Total
Balance at Dec. 31, 2020	$ 304	$ 10,463	$ (635)	$ (11,836)	$ (1,704)
Changes during the period:
Net loss				(8,290)	(8,290)
Other comprehensive loss			(33)		(33)
Total comprehensive loss			(33)	(8,290)	(8,323)
Per value cancellation	(304)	304
Options exercise
Share base compensation		462			462
Balance at Jun. 30, 2021		11,229	(668)	(20,126)	(9,565)
Balance at Dec. 31, 2021		48,935	210	(28,791)	20,354
Changes during the period:
Net loss				(3,473)	(3,473)
Other comprehensive loss			(2,235)		(2,235)
Total comprehensive loss			(2,235)	(3,473)	(5,708)
Share base compensation		3,107			3,107
Balance at Jun. 30, 2022		$ 52,042	$ (2,025)	$ (32,264)	$ 17,753

Unaudited Interim Condensed S_5

Unaudited Interim Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,473)	$ (8,290)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	98	93
Increase (decrease) in other accounts receivable	400	(180)
Increase (decrease) in trade accounts payables	(35)	6
Increase (decrease) in other accounts payable	503	(77)
Share based compensation	3,107	462
Change in fair value of Financial Liabilities at fair value	(2,586)	5,549
Financial income	(27)
Financial expenses	51	107
Net cash used in operating activities	(1,962)	(2,330)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(55)	(41)
Deposits	(4,994)
Payment of deposit	42	(857)
Net cash provided investing activities	(5,007)	(898)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal paid on lease liabilities	(155)	(106)
Receipt of SAFE proceeds		4,112
Receipt convertible loan		3,484
Payment of convertible loan		(431)
Loan from the Israeli Innovation Authority		55
Net cash provided financing activities	(155)	7,114
Net increase in cash and cash equivalents	(7,124)	3,886
Cash and cash equivalents at the beginning of the period	23,749	496
Effects of exchange rate changes on cash and cash equivalents	(2,471)	(27)
Cash and cash equivalents at the end of the period	$ 14,154	$ 4,355

General

General	6 Months Ended
	Jun. 30, 2022
Disclosure Of General And Administrative Expense Text Block Abstract
GENERAL	NOTE 1 – GENERAL: 1. INSPIRA TECHNOLOGIES OXY B.H.N. LTD (formerly: INSENSE MEDICAL LTD) (the “Company”) was incorporated in, Israel and commenced its operations on February 27, 2018. The Company’s functional currency is the New Israeli Shekel (“NIS”). The Company operates in the medical technology industry and is developing a proprietary respiratory support device called the “Inspira ART system”. The Inspira ART system is a cost effective, early extracorporeal respiratory support system with an intent to function as an “artificial lung” for deteriorating respiratory patients. The Inspira ART system is designed to utilize a hemo-protective flow approach aimed to rebalance saturation levels while patients are awake and breathing, potentially minimizing the patient’s need for mechanical ventilation. The Company’s product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA). On July 16, 2021, the Company completed its initial public offering (“IPO”) Nasdaq Capital Market whereby the Company sold 2,909,091 of its ordinary shares (the “Ordinary Shares”) and 3,345,455 tradable warrants (inclusive of 436,364 tradable warrants pursuant to the exercise of an overallotment option granted to the underwriters). The aggregate proceeds received by the Company from the IPO were $14,500, after deducting underwriting discounts and commissions and additional offering costs. On July 16, 2021, following the IPO, the Company issued 2,113,905 ordinary shares and 1,149,582 warrants to investors in connection with the conversion of Company’s previously issued financial liabilities at fair value. 2. The Company has not generated any revenue since its inception, and the Company is still at the development stage of its products. The Company’s operating loss for the six-months ended June 30, 2022 and 2021 were 8,007 and 2,558 , respectively, and the Company’s net loss for the same period was 3,473 and 8,290. As of June 30, 2022, the company had an accumulated deficit of 32,264. The Company has funded its operations through the proceeds of the IPO. The Company has also the ability to decrease its expenses in order to meet its existing cash flow streams. Management believes that the proceeds of the fundings agreements, combined with its cash on hand and the Company plans, are sufficient to meet the Company’s obligations as they come due in the foreseeable future. There are no assurances, however, that the Company will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of its product offering. The Company does not have any material financial obligations as of the balance date. 3. The global pandemic resulting from the disease known as COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions and may adversely impact our business. Although the Company continued to operate almost fully including carrying out the studies in compliance with all applicable Israeli rules and guidelines on COVID-19, the employees worked remotely when full lockdowns were enforced. The spread of an infectious disease, including COVID-19, may also result in the inability of the manufacturers to deliver components or finished products on a timely basis and may result in the inability of the Company’s suppliers to deliver the parts required by the manufacturers to complete manufacturing of components or finished products. The Company cannot predict the duration or magnitude of the pandemic or the full impact that it may have on the Company’s operations and workforce, including the Company’s research and clinical trials and its ability to raise capital, which in turn could have an adverse impact on the Company’s business, financial condition and results of operation.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Disclosure Of Significant Accounting Policies Text Block Abstract
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 SIGNIFICANT ACCOUNTING POLICIES: The principal accounting policies adopted in the preparation of the financial statements are set out below. The policies have been consistently applied to all the years presented, unless otherwise stated. Basis of preparation These interim condensed financial statements have been prepared in accordance with the International Accounting Standards (the “IAS”) 34 Interim Financial Reporting, as issued by the International Accounting Standards Board (IASB). They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with the 2021 annual financial statements filed with the Company’s annual report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 31, 2022. The Company has applied the same accounting policies and methods of computation in its interim financial statements as in its 2022 annual financial statements. Impact of accounting standards to be applied in future periods There are a number of standards and interpretations which have been issued by the IAS Board that are effective for periods beginning subsequent to December 31, 2022 (the date on which the Company’s next annual financial statements will be prepared up to) that the Company has decided not to adopt early. The Company does not believe these standards and interpretations will have a material impact on the financial statements once adopted.

Other Accounts Payable

Other Accounts Payable	6 Months Ended
	Jun. 30, 2022
Description Of Accounting Policy For Trade And Other Payables Text Block Abstract
OTHER ACCOUNTS PAYABLE	NOTE 3 – OTHER ACCOUNTS PAYABLE: June 30, December 31, Employees’ salaries and related liabilities 545 614 Accrued expenses 546 82 Other 23 29 Total 1,114 725

Finacial Liabilities Value

Finacial Liabilities Value	6 Months Ended
	Jun. 30, 2022
Finacial Liabilities Value [Abstract]
FINACIAL LIABILITIES VALUE	NOTE 4 – FINACIAL LIABILITIES VALUE: June 30, 2022 December 31, Non-tradable warrants (1) 5 196 Non-tradable warrants of SAFE and Convertible Loan investors (2) 56 1,393 Tradable warrants (3) 357 1,493 Financial liability (4) 21 133 Total 439 3,215 1. Non-Tradable Warrants As part of an agreement signed in 2019, the investors of certain convertibles loan received, upon conversion to shares 756,333 Ordinary Shares to investors and promoters, non-tradable warrants to purchase an additional 169,019 Ordinary Shares upon consummation of an IPO on the Nasdaq. The warrants are exercisable into Ordinary Shares of the Company at an exercise price equal to the initial public offering price and are exercisable for three years after the IPO. The warrants were designated to be measured at fair value through profit or loss. On July 2021, as part of the IPO, the investors received the specified warrants. As of June 30, 2022, the fair value of the warrants were $5. 2. Non-tradable warrants, SAFE and Convertible Loan investors On July 16, 2021, following the IPO, the Company issued 2,113,905 Ordinary Shares and 1,149,582 non-tradable warrants to investors in connection with the conversion of Company’s CLAs and SAFEs according to their terms, the fair value of the shares was classified as equity with total value of $10,041. The non-tradable warrants were designated to be measured at fair value through profit or loss. The non-tradable warrants fair value as of June 30, 2022 is $56. 3. Tradable warrants The Company sold 3,345,455 tradable warrants in the IPO. As of June 30, 2022, 1,705,000 tradable warrants were exercised. In October 2021, investors exercised 1,705,000 tradable warrants whereby the Company issued 1,705,000 Ordinary Shares to such investors. The total proceeds received by the Company from this exercise was approximately $9,377. The net proceeds after fees deducting were approximately $8,721. The tradable warrants were designated to be measured at fair value through profit or loss. The tradable warrants fair value as of June 30, 2022, is $357. 4. Financial liability Financial liability to pay 7% fees on the fundings that will be received from exercises of tradable warrants. The fair value as of June 30, 2022 is $21.

Share Based Compensation

Share Based Compensation	6 Months Ended
	Jun. 30, 2022
Disclosure Of Share Based Payment Arrangements Text Block Abstract
SHARE BASED COMPENSATION	NOTE 5 - SHARE BASED COMPENSATION: In December 2019, the Company established a share option plan (the “Plan”). As of June 30, 2022, a total of 505,473 options to subscribe Ordinary Shares have been granted to employees, consultants and directors under the Plan, and a total of 3,542,542 restricted stock units (“RSUs”)have been granted to employees, consultants and directors under the Plan, of which 1,404,846 RSUs are vested as of June 30, 2022. On March 24, 2022, the Company’s board of directors approved a grant of 536,141 RSUs to employees and a grant of 22,500 RSUs to the Company’s advisory board members and an additional consultant. The RSUs represents the right to receive Ordinary Shares at a future time. 555,500 RSU’s vest over a period of three years, with 1 year cliff and 3,141 RSUs vested immediately on the grant date. The RSUs to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise. On March 24, 2022, the Company’s board of directors granted a total of 29,400 options to subscribe for Ordinary Shares to advisory board members. The vesting period is three years commencing on the grant date, with 1 year cliff. The exercise price per share was NIS 0.37($0.12). The contractual life of the options under the Plan is ten years. On April 6, 2022, the Company’s board of directors approved a grant of fully vested 285,713 RSUs to an officer. The RSUs represents the right to receive Ordinary Shares . The RSUs were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise. On May 19, 2022, the Company’s board of directors approved a grant of 30,000 RSUs to an employee. The RSUs represents the right to receive Ordinary Shares at a future time and vest over a period of three years, with 1 year cliff period, commencing on the grant date. The RSUs were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise. The fair value of all granted options was estimated by using the Black Scholes model, which was aimed to model the value of the Company’s assets over time. The simulation approach was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and the volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others: (i) The expected volatility is 50%; (ii) The dividend rate 0%; and (iii) Expected term – three years. The valuation was completed with the assistance of an external valuator based on management’s assumptions. During the six months ended June 30, 2022, the Company recorded share-based payment expenses in the amount of $3,107. The options to services providers and advisers outstanding as of June 30, 2022, as follows: Six months ended Number of options Weighted average Outstanding at beginning of year 87,833 0.37 Granted 29,400 10.78 Exercised (2,721 ) 0.37 Forfeited - - Outstanding as of June 30, 2022 114,512 3.041 Exercisable options 71826 0.37 During the six-months ended June 30, 2022, the Company recorded share-based payment expenses of option to services providers and advisers in the amount of $22. The RSUs to services providers and advisers outstanding as of June 30, 2022, as follows: Number of RSUs Outstanding at beginning of year 10,000 Granted 22,500 Vested 1,666 Outstanding as of June 30, 2022 30,834 Vested as of June 30, 2022 1,666 During the six-months ended June 30, 2022, the Company recorded share-based payment expenses of RSUs to services providers and advisers in the amount of $22. The options to employees and directors outstanding as of June 30, 2022, as follows: Six months ended Number of options Weighted average Outstanding at beginning of year 448,120 0.37 Forfeited (57,159 ) 0.37 Outstanding as of June 30, 2022 390,961 0.37 Exercisable options 324,727 0.37 During the six-months ended June 30, 2022, the Company recorded share-based payment expenses of options to employees and directors in the amount of $110. The RSUs to employees and directors outstanding as of June 30, 2022, as follows: Number of RSUs Outstanding at beginning of year 2,002,587 Granted 826,854 Vested 747,579 Outstanding as of June 30, 2022 2,081,862 Vested as of June 30, 2022 1,403,180 During the six-months ended June 30, 2022, the Company recorded share-based payment expenses of RSUs to employees and directors in the amount of $2,953.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2022
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Equity Text Block Abstract
FAIR VALUE MEASUREMENT	NOTE 6 - FAIR VALUE MEASUREMENT: Fair value hierarchy The following tables detail the Company’s assets and liabilities, measured or disclosed at fair value, using a three-level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs for the asset or liability. As of June 30, 2022: Level 1 Level 2 Level 3 Non-Tradable Warrants - 56 - Non-tradable warrants of SAFE and Convertible Loan investors 5 Financial liability - 21 - Tradable warrants 357 - - Total 357 82 - As of December 31, 2021: Level 1 Level 2 Level 3 Non-Tradable Warrants - 196 - Non-tradable warrants of SAFE and Convertible Loan investors 1,393 Financial liability - 133 - Tradable warrants 1,493 - - Total 1,493 1,722 - As of June 30, 2022, the fair value measurement of the warrant’s securities in the table above, was estimated using the Black Scholes model, based on assumptions for the variable that are required as of the warrants’ valuation date. The key inputs that were used in the both items of non-tradable warrants valuation were: risk-free interest rate between 3.83% and 3.86%, expected volatility between 53.2%-58.3% , expected dividend yield of 0% and expected term of warrants of – 2.04-3.04 years. As of December 31, 2021, the fair value measurement of the SAFE and the warrant’s securities in the table above, was estimated using the Black Scholes model, based on a variety of significant unobservable inputs a thus represent a level 2 measurement within the fair value hierarchy. The key inputs that were used in the both items of non-tradable warrants valuation were: risk-free interest rate between 0.19% and 0.73% ,expected volatility between 55.3%-57.8% , expected dividend yield of 0% and expected term of warrants of – 2.54-3.54 years. The carrying amounts of trade and other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature. Movements in level 3 assets and liabilities during the corresponding period are set out below: Warrants SAFE Convertible Balance at December 31, 2020 219 1,273 - Gains (losses) recognized in profit or loss 111 4,005 1,492 Gains (losses) recognized in other comprehensive loss - (20 ) 37 Additions - 4,112 3,053 Balance at June, 30 2021 330 9,370 4,582

Significant Events During the P

Significant Events During the Period	6 Months Ended
	Jun. 30, 2022
Significant Events And Transactions In The Period Abstract
SIGNIFICANT EVENTS DURING THE PERIOD:	NOTE 7 – SIGNIFICANT EVENTS DURING THE PERIOD: On March 4, 2022, a service provider filed a complaint against the Company in connection with a contract between the parties. To date, the Company has not been formally served with the complaint. The Company’s management and the Company’s legal counsel believe it is more likely than not that the complaint will be dismissed based on the language of the written contract between the parties.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of preparation	Basis of preparation These interim condensed financial statements have been prepared in accordance with the International Accounting Standards (the “IAS”) 34 Interim Financial Reporting, as issued by the International Accounting Standards Board (IASB). They do not include all disclosures that would otherwise be required in a complete set of financial statements and should be read in conjunction with the 2021 annual financial statements filed with the Company’s annual report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 31, 2022. The Company has applied the same accounting policies and methods of computation in its interim financial statements as in its 2022 annual financial statements.
Impact of accounting standards to be applied in future periods	Impact of accounting standards to be applied in future periods There are a number of standards and interpretations which have been issued by the IAS Board that are effective for periods beginning subsequent to December 31, 2022 (the date on which the Company’s next annual financial statements will be prepared up to) that the Company has decided not to adopt early. The Company does not believe these standards and interpretations will have a material impact on the financial statements once adopted.

Other Accounts Payable (Tables)

Other Accounts Payable (Tables)	6 Months Ended
	Jun. 30, 2022
Description Of Accounting Policy For Trade And Other Payables Text Block Abstract
Schedule of other accounts payable	June 30, December 31, Employees’ salaries and related liabilities 545 614 Accrued expenses 546 82 Other 23 29 Total 1,114 725

Finacial Liabilities Value (Tab

Finacial Liabilities Value (Tables)	6 Months Ended
	Jun. 30, 2022
Finacial Liabilities Value [Abstract]
Schedule of financial liabilities value	June 30, 2022 December 31, Non-tradable warrants (1) 5 196 Non-tradable warrants of SAFE and Convertible Loan investors (2) 56 1,393 Tradable warrants (3) 357 1,493 Financial liability (4) 21 133 Total 439 3,215 1. Non-Tradable Warrants As part of an agreement signed in 2019, the investors of certain convertibles loan received, upon conversion to shares 756,333 Ordinary Shares to investors and promoters, non-tradable warrants to purchase an additional 169,019 Ordinary Shares upon consummation of an IPO on the Nasdaq. The warrants are exercisable into Ordinary Shares of the Company at an exercise price equal to the initial public offering price and are exercisable for three years after the IPO. The warrants were designated to be measured at fair value through profit or loss. On July 2021, as part of the IPO, the investors received the specified warrants. As of June 30, 2022, the fair value of the warrants were $5. 2. Non-tradable warrants, SAFE and Convertible Loan investors On July 16, 2021, following the IPO, the Company issued 2,113,905 Ordinary Shares and 1,149,582 non-tradable warrants to investors in connection with the conversion of Company’s CLAs and SAFEs according to their terms, the fair value of the shares was classified as equity with total value of $10,041. The non-tradable warrants were designated to be measured at fair value through profit or loss. The non-tradable warrants fair value as of June 30, 2022 is $56. 3. Tradable warrants The Company sold 3,345,455 tradable warrants in the IPO. As of June 30, 2022, 1,705,000 tradable warrants were exercised. In October 2021, investors exercised 1,705,000 tradable warrants whereby the Company issued 1,705,000 Ordinary Shares to such investors. The total proceeds received by the Company from this exercise was approximately $9,377. The net proceeds after fees deducting were approximately $8,721. The tradable warrants were designated to be measured at fair value through profit or loss. The tradable warrants fair value as of June 30, 2022, is $357. 4. Financial liability Financial liability to pay 7% fees on the fundings that will be received from exercises of tradable warrants.

Share Based Compensation (Table

Share Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure Of Share Based Payment Arrangements Text Block Abstract
Schedule of services providers outstanding	Six months ended Number of options Weighted average Outstanding at beginning of year 87,833 0.37 Granted 29,400 10.78 Exercised (2,721 ) 0.37 Forfeited - - Outstanding as of June 30, 2022 114,512 3.041 Exercisable options 71826 0.37 Six months ended Number of options Weighted average Outstanding at beginning of year 448,120 0.37 Forfeited (57,159 ) 0.37 Outstanding as of June 30, 2022 390,961 0.37 Exercisable options 324,727 0.37
Schedule of restricted shares units to employees and directors outstanding	Number of RSUs Outstanding at beginning of year 10,000 Granted 22,500 Vested 1,666 Outstanding as of June 30, 2022 30,834 Vested as of June 30, 2022 1,666 Number of RSUs Outstanding at beginning of year 2,002,587 Granted 826,854 Vested 747,579 Outstanding as of June 30, 2022 2,081,862 Vested as of June 30, 2022 1,403,180

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Equity Text Block Abstract
Schedule of unobservable inputs for the asset or liability	Level 1 Level 2 Level 3 Non-Tradable Warrants - 56 - Non-tradable warrants of SAFE and Convertible Loan investors 5 Financial liability - 21 - Tradable warrants 357 - - Total 357 82 - Level 1 Level 2 Level 3 Non-Tradable Warrants - 196 - Non-tradable warrants of SAFE and Convertible Loan investors 1,393 Financial liability - 133 - Tradable warrants 1,493 - - Total 1,493 1,722 -
Schedule of level 3 assets and liabilities during the current and previous financial year	Warrants SAFE Convertible Balance at December 31, 2020 219 1,273 - Gains (losses) recognized in profit or loss 111 4,005 1,492 Gains (losses) recognized in other comprehensive loss - (20 ) 37 Additions - 4,112 3,053 Balance at June, 30 2021 330 9,370 4,582

General (Details)

General (Details) - USD ($) $ in Thousands		6 Months Ended
	Jul. 16, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure Of General And Administrative Expense Text Block Abstract
Number of shares (in Shares)	2,909,091
Tradable warrants shares (in Shares)	3,345,455
Warrants pursuant shares (in Shares)	436,364
Aggregate proceeds amount			$ 14,500
Ordinary shares (in Shares)	2,113,905
Warrants shares (in Shares)	1,149,582
Operating loss		$ 8,007	2,558
Net loss		3,473	$ (8,290)
Accumulated deficit		$ 32,264

Other Accounts Payable (Details

Other Accounts Payable (Details) - Schedule of other accounts payable - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Other Accounts Payable Abstract
Employees’ salaries and related liabilities	$ 545	$ 614
Accrued expenses	546	82
Other	23	29
Total	$ 1,114	$ 725

Finacial Liabilities Value (Det

Finacial Liabilities Value (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Jul. 16, 2021	Jun. 30, 2022
Finacial Liabilities Value [Abstract]
Conversion rate, description		As part of an agreement signed in 2019, the investors of certain convertibles loan received, upon conversion to shares 756,333 Ordinary Shares to investors and promoters, non-tradable warrants to purchase an additional 169,019 Ordinary Shares upon consummation of an IPO on the Nasdaq.
Fair value of warrants		$ 5
Nontradable warrants, description	On July 16, 2021, following the IPO, the Company issued 2,113,905 Ordinary Shares and 1,149,582 non-tradable warrants to investors in connection with the conversion of Company’s CLAs and SAFEs according to their terms, the fair value of the shares was classified as equity with total value of $10,041. The non-tradable warrants were designated to be measured at fair value through profit or loss.
Non-tradable warrants amount		$ 56
Tradable warrants, description		The Company sold 3,345,455 tradable warrants in the IPO. As of June 30, 2022, 1,705,000 tradable warrants were exercised. In October 2021, investors exercised 1,705,000 tradable warrants whereby the Company issued 1,705,000 Ordinary Shares to such investors.
Total proceeds received		$ 9,377
Net proceeds		8,721
Tradable warrants		$ 357
Tradable warrants rate		7%
Total fair value		$ 21

Finacial Liabilities Value (D_2

Finacial Liabilities Value (Details) - Schedule of financial liabilities value - USD ($) $ in Thousands		6 Months Ended	12 Months Ended
		Jun. 30, 2022	Dec. 31, 2021
Schedule Of Financial Liabilities Value Abstract
Non-tradable warrants	[1]	$ 5	$ 196
Non-tradable warrants of SAFE and Convertible Loan investors	[2]	56	1,393
Tradable warrants	[3]	357	1,493
Financial liability	[4]	21	133
Total		$ 439	$ 3,215
[1]Non-Tradable WarrantsAs part of an agreement signed in 2019, the investors of certain convertibles loan received, upon conversion to shares 756,333 Ordinary Shares to investors and promoters, non-tradable warrants to purchase an additional 169,019 Ordinary Shares upon consummation of an IPO on the Nasdaq. The warrants are exercisable into Ordinary Shares of the Company at an exercise price equal to the initial public offering price and are exercisable for three years after the IPO.The warrants were designated to be measured at fair value through profit or loss.On July 2021, as part of the IPO, the investors received the specified warrants. As of June 30, 2022, the fair value of the warrants were $5.[2]Non-tradable warrants, SAFE and Convertible Loan investorsOn July 16, 2021, following the IPO, the Company issued 2,113,905 Ordinary Shares and 1,149,582 non-tradable warrants to investors in connection with the conversion of Company’s CLAs and SAFEs according to their terms, the fair value of the shares was classified as equity with total value of $10,041. The non-tradable warrants were designated to be measured at fair value through profit or loss.The non-tradable warrants fair value as of June 30, 2022 is $56.[3]Tradable warrantsThe Company sold 3,345,455 tradable warrants in the IPO. As of June 30, 2022, 1,705,000 tradable warrants were exercised. In October 2021, investors exercised 1,705,000 tradable warrants whereby the Company issued 1,705,000 Ordinary Shares to such investors. The total proceeds received by the Company from this exercise was approximately $9,377. The net proceeds after fees deducting were approximately $8,721.The tradable warrants were designated to be measured at fair value through profit or loss.The tradable warrants fair value as of June 30, 2022, is $357.[4]Financial liabilityFinancial liability to pay 7% fees on the fundings that will be received from exercises of tradable warrants.

Share Based Compensation (Detai

Share Based Compensation (Details)		1 Months Ended			6 Months Ended
	Apr. 06, 2022 shares	May 19, 2022 shares	Mar. 24, 2022 $ / shares shares	Dec. 31, 2019	Jun. 30, 2022 USD ($) shares
Share Based Compensation (Details) [Line Items]
Options granted				505,473
Vested shares (in Shares) | shares					1,404,846
Share based compensation related party description			The RSUs represents the right to receive Ordinary Shares at a future time. 555,500 RSU’s vest over a period of three years, with 1 year cliff and 3,141 RSUs vested immediately on the grant date. The RSUs to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.
Granted total options (in Shares) | shares		30,000	29,400
Exercise price (in Dollars per share) | $ / shares			$ 0.12
Contractual life			10 years
Capital gain tax	25%	25%
Description of fair value assumptions					The fair value of all granted options was estimated by using the Black Scholes model, which was aimed to model the value of the Company’s assets over time. The simulation approach was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company and the volatility of its assets, on the date of grant based on certain assumptions. Those conditions are, among others:  (i)The expected volatility is 50%;   (ii)The dividend rate 0%; and   (iii)Expected term – three years.
Share based payment expenses					$ 3,107,000
Restricted Stock Units [Member]
Share Based Compensation (Details) [Line Items]
Options granted				3,542,542
Shares vested (in Shares) | shares	285,713
Restricted Stock Units [Member] | Services providers and advisers [Member]
Share Based Compensation (Details) [Line Items]
Share based payment expenses					22
Restricted Stock Units [Member] | Employees and directors [Member]
Share Based Compensation (Details) [Line Items]
Share based payment expenses					2,953
Stock Options [Member] | Services providers and advisers [Member]
Share Based Compensation (Details) [Line Items]
Share based payment expenses					22
Stock Options [Member] | Employees and directors [Member]
Share Based Compensation (Details) [Line Items]
Share based payment expenses					$ 110

Share Based Compensation (Det_2

Share Based Compensation (Details) - Schedule of services providers outstanding	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Services providers and advisers [Member]
Share Based Compensation (Details) - Schedule of services providers outstanding [Line Items]
Number of options, Outstanding at beginning | shares	87,833
Weighted average Exercise price NIS, Outstanding at beginning | $ / shares	$ 0.37
Number of options, Granted | shares	29,400
Weighted average Exercise price NIS, Granted | $ / shares	$ 10.78
Number of options, Exercised | shares	(2,721)
Weighted average Exercise price NIS, Exercised | $ / shares	$ 0.37
Number of options, Forfeited | shares
Weighted average Exercise price NIS, Forfeited | $ / shares
Number of options, Outstanding at ending | shares	114,512
Weighted average Exercise price NIS, Outstanding at ending | $ / shares	$ 3.041
Number of options, Exercisable options | shares	71,826
EWeighted average Exercise price NIS, Exercisable options | $ / shares	$ 0.37
Employees and directors [Member]
Share Based Compensation (Details) - Schedule of services providers outstanding [Line Items]
Number of options, Outstanding at beginning | shares	448,120
Weighted average Exercise price NIS, Outstanding at beginning | $ / shares	$ 0.37
Number of options, Forfeited | shares	(57,159)
Weighted average Exercise price NIS, Forfeited | $ / shares	$ 0.37
Number of options, Outstanding at ending | shares	390,961
Weighted average Exercise price NIS, Outstanding at ending | $ / shares	$ 0.37
Number of options, Exercisable options | shares	324,727
EWeighted average Exercise price NIS, Exercisable options | $ / shares	$ 0.37

Share Based Compensation (Det_3

Share Based Compensation (Details) - Schedule of restricted shares units to employees and directors outstanding	6 Months Ended
	Jun. 30, 2022 shares
Share Based Compensation (Details) - Schedule of restricted shares units to employees and directors outstanding [Line Items]
Outstanding at beginning	10,000
Granted	22,500
Vested	1,666
Outstanding at ending	30,834
Vested as of June 30, 2022	1,666
Number of RSUs [Member]
Share Based Compensation (Details) - Schedule of restricted shares units to employees and directors outstanding [Line Items]
Outstanding at beginning	2,002,587
Granted	826,854
Vested	747,579
Outstanding at ending	2,081,862
Vested as of June 30, 2022	1,403,180

Fair Value Measurement (Details

Fair Value Measurement (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Fair Value Measurement (Details) [Line Items]
Expected dividend yield	0%	0%
Bottom of range [Member]
Fair Value Measurement (Details) [Line Items]
Interest rate	3.83%	0.19%
Expected volatility	53.20%	55.30%
Expected term of warrant	2 years 14 days	2 years 6 months 14 days
Top of range [Member]
Fair Value Measurement (Details) [Line Items]
Interest rate	3.86%	0.73%
Expected volatility	58.30%	57.80%
Expected term of warrant	3 years 14 days	3 years 6 months 14 days

Fair Value Measurement (Detai_2

Fair Value Measurement (Details) - Schedule of unobservable inputs for the asset or liability - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Level 2 [Member]
Fair Value Measurement (Details) - Schedule of unobservable inputs for the asset or liability [Line Items]
Fair value	$ 82	$ 1,722
Level 1 [Member]
Fair Value Measurement (Details) - Schedule of unobservable inputs for the asset or liability [Line Items]
Fair value	357	1,493
Level 3 [Member]
Fair Value Measurement (Details) - Schedule of unobservable inputs for the asset or liability [Line Items]
Fair value
Warrants [Member] | Level 2 [Member]
Fair Value Measurement (Details) - Schedule of unobservable inputs for the asset or liability [Line Items]
Fair value	56	196
Convertible loan [Member] | Level 2 [Member]
Fair Value Measurement (Details) - Schedule of unobservable inputs for the asset or liability [Line Items]
Fair value	5
Financial liability [Member] | Level 2 [Member]
Fair Value Measurement (Details) - Schedule of unobservable inputs for the asset or liability [Line Items]
Fair value	21	133
Tradable warrants [Member] | Level 1 [Member]
Fair Value Measurement (Details) - Schedule of unobservable inputs for the asset or liability [Line Items]
Fair value	$ 357	1,493
SAFE [Member] | Level 2 [Member]
Fair Value Measurement (Details) - Schedule of unobservable inputs for the asset or liability [Line Items]
Fair value		$ 1,393

Fair Value Measurement (Detai_3

Fair Value Measurement (Details) - Schedule of level 3 assets and liabilities during the current and previous financial year $ in Thousands	6 Months Ended
	Jun. 30, 2021 USD ($)
Warrants [Member]
Fair Value Measurement (Details) - Schedule of level 3 assets and liabilities during the current and previous financial year [Line Items]
Balance beginning	$ 219
Gains (losses) recognized in profit or loss	111
Gains (losses) recognized in other comprehensive loss
Additions
Balance ending	330
SAFE [Member]
Fair Value Measurement (Details) - Schedule of level 3 assets and liabilities during the current and previous financial year [Line Items]
Balance beginning	1,273
Gains (losses) recognized in profit or loss	4,005
Gains (losses) recognized in other comprehensive loss	(20)
Additions	4,112
Balance ending	9,370
Convertible loan [Member]
Fair Value Measurement (Details) - Schedule of level 3 assets and liabilities during the current and previous financial year [Line Items]
Balance beginning
Gains (losses) recognized in profit or loss	1,492
Gains (losses) recognized in other comprehensive loss	37
Additions	3,053
Balance ending	$ 4,582